Cochlear zinc signaling dysregulation is associated with noise-induced hearing loss, and zinc chelation enhances cochlear recovery
Proceedings of the National Academy of Sciences · 2024
DOI: 10.1073/pnas.2310561121 ↗Kurz gefasst
Fachartikel in der Zeitschrift Proceedings of the National Academy of Sciences, 2024. Verfasst von Brandon Bizup und 4 weiteren Autor:innen. Beteiligte Einrichtung: Pittsburgh Hearing Research Center, Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA 15261. Hauptthemen laut MEDLINE: Hearing Loss, Noise-Induced. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 99 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: NIDCD NIH HHS, NIA NIH HHS, NIBIB NIH HHS.
Abstract (Originalsprache)
Exposure to loud noise triggers sensory organ damage and degeneration that, in turn, leads to hearing loss. Despite the troublesome impact of noise-induced hearing loss (NIHL) in individuals and societies, treatment strategies that protect and restore hearing are few and insufficient. As such, identification and mechanistic understanding of the signaling pathways involved in NIHL are required. Biological zinc is mostly bound to proteins, where it plays major structural or catalytic roles; however, there is also a pool of unbound, mobile (labile) zinc. Labile zinc is mostly found in vesicles in secretory tissues, where it is released and plays a critical signaling role. In the brain, labile zinc fine-tunes neurotransmission and sensory processing. However, injury-induced dysregulation of labile zinc signaling contributes to neurodegeneration. Here, we tested whether zinc dysregulation occurs and contributes to NIHL in mice. We found that ZnT3, the vesicular zinc transporter responsible for loading zinc into vesicles, is expressed in cochlear hair cells and the spiral limbus, with labile zinc also present in the same areas. Soon after noise trauma, ZnT3 and zinc levels are significantly increased, and their subcellular localization is vastly altered. Disruption of zinc signaling, either via ZnT3 deletion or pharmacological zinc chelation, mitigated NIHL, as evidenced by enhanced auditory brainstem responses, distortion product otoacoustic emissions, and number of hair cell synapses. These data reveal that noise-induced zinc dysregulation is associated with cochlear dysfunction and recovery after NIHL, and point to zinc chelation as a potential treatment for mitigating NIHL.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Pittsburgh Hearing Research Center, Department of Otolaryngology, University of Pittsburgh, Pittsburgh, PA 15261.
- Department of Neurobiology, University of Pittsburgh, Pittsburgh, PA 15261.
ORCID-Profile: Christopher L Cunningham, Amantha Thathiah
Förderung
- NIDCD NIH HHS
- NIA NIH HHS
- NIBIB NIH HHS
- HHS | NIH | National Institute on Deafness and Other Communication Disorders
- HHS | NIH | National Institute of Biomedical Imaging and Bioengineering
- HHS | NIH | National Institute on Aging
Zitieren
APA
Bizup, B., Brutsaert, S., Cunningham, C. L., Thathiah, A., & Tzounopoulos, T. (2024). Cochlear zinc signaling dysregulation is associated with noise-induced hearing loss, and zinc chelation enhances cochlear recovery. Proceedings of the National Academy of Sciences. https://doi.org/10.1073/pnas.2310561121
Vancouver
Bizup B, Brutsaert S, Cunningham CL, Thathiah A, Tzounopoulos T. Cochlear zinc signaling dysregulation is associated with noise-induced hearing loss, and zinc chelation enhances cochlear recovery. Proceedings of the National Academy of Sciences. 2024. doi:10.1073/pnas.2310561121
BibTeX
@article{Bizup2024,
author = {Bizup, Brandon and Brutsaert, Sofie and Cunningham, Christopher L and Thathiah, Amantha and Tzounopoulos, Thanos},
title = {Cochlear zinc signaling dysregulation is associated with noise-induced hearing loss, and zinc chelation enhances cochlear recovery},
journal = {Proceedings of the National Academy of Sciences},
year = {2024},
doi = {10.1073/pnas.2310561121}
}
EUVIMED